2022 World Conference on Lung Cancer (ePosters)-EP08.02-132. Fatal Interstitial lung disease induced by Osimertinib: a case report

Pdf Summary

This case report discusses a rare adverse effect of the EGFR-TKI inhibitor, Osimertinib, which is used in the treatment of metastatic lung adenocarcinoma. The patient in this case was an 81-year-old female with stage IVB lung adenocarcinoma and metastasis in the lungs, adrenal glands, and brain. She had a past medical history of diabetes and dyslipidemia.<br /><br />The report highlights that interstitial lung disease (ILD) is a rare side effect of Osimertinib, and fatal ILD is even rarer. The time it takes for this side effect to occur varies among patients, indicating the need for awareness, rapid diagnosis, and early treatment.<br /><br />The report also mentions other studies that have shown cases of continuing Osimertinib without clinical worsening and gradual improvement in ground glass opacities in patients without symptoms. In addition, literature review has revealed that the recurrence of ILD can be prevented by using corticosteroids.<br /><br />The report provides information from two clinical studies, FLAURA and CHINA FLAURA, which reported ILD adverse events in a small percentage of patients, but no fatal ILD events in the Osimertinib group.<br /><br />The case presentation describes the patient's journey from being treated with Erlotinib due to an EGFR exon 19 deletion to starting Osimertinib after the detection of a T790M resistance mutation in a liquid biopsy. Two months after starting Osimertinib, the patient experienced dyspnea, cough, and fever leading to hospitalization.<br /><br />The patient's condition worsened over time, and despite various interventions, including oxygen therapy and IV antibiotics, she ultimately experienced respiratory distress, hypoxemia, and hypotension. Palliative care was initiated, and the patient passed away.<br /><br />This case report serves as a reminder of the potential rare and fatal adverse effects of Osimertinib in the treatment of metastatic lung adenocarcinoma and emphasizes the importance of vigilant monitoring and prompt management to improve patient outcomes.

Asset Subtitle

Ricardo José Cordeiro

Meta Tag

Speaker Ricardo José Cordeiro

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EGFR-TKI inhibitor

Osimertinib

metastatic lung adenocarcinoma

rare adverse effect

interstitial lung disease

fatal ILD

rapid diagnosis

early treatment

ground glass opacities

recurrence of ILD